NCT04076631

Brief Summary

The investigators intend to perform a prospective, multicenter study to establish a set of clinical criteria for surgical stages of liver cirrhosis, which can be implemented to guide the surgical treatment of hepatocellular carcinoma (HCC).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2019

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2019

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

August 13, 2019

Completed
21 days until next milestone

First Posted

Study publicly available on registry

September 3, 2019

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

October 12, 2020

Status Verified

October 1, 2020

Enrollment Period

1.3 years

First QC Date

August 13, 2019

Last Update Submit

October 9, 2020

Conditions

Outcome Measures

Primary Outcomes (3)

  • Preoperative assessment of cirrhotic severity by cirrhotic severity scoring (TJ-CSS)

    The calculation of TJ-CSS will be based on four clinical parameters (esophageal varices severity, portal vein diameter, spleen thickness and platelet account).

    within 10 days prior to hepatectomy

  • Liver stiffness measurement

    Liver stiffness will be measured by LX-C Shaw hardmeter.

    during operation

  • Pathological stage of liver cirrhosis

    Liver cirrhosis will be sub-staged according to Laennec staging system

    Within 30 days after surgery

Secondary Outcomes (1)

  • The effect of cirrhotic severity and extent of hepatectomy on the incidence of post-hepatectomy liver failure (PHLF)

    postoperative day 5

Study Arms (1)

Hepatocellular Carcinoma

Patients with hepatocellular carcinoma undergo open hepatectomy.

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who undergo open liver resection with curative intent for HCC and meet the eligibility criteria from 6 hospitals in China (Wuhan Tongji Hospital, Wuhan Union Hospital, Wuhan Zhongnan hospital, Hubei Cancer Hospital, Shiyan Taihe Hospital, Xiangyang Central Hospital) will be selected.

You may qualify if:

  • Male or female, 18 to 75 years of age, inclusive.
  • Patients who are clinically diagnosed as hepatocellular carcinoma and confirmed by postoperative pathology.
  • The liver function grade was Child-Pugh class A or class B, which can be restored to Child-Pugh class A within a short period of medical treatment.
  • Patients who undergo open surgery.
  • Patients have not been accompanied by serious physical diseases of heart, lung, brain, etc., and can generally tolerable for surgery.
  • Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if:

  • Patients with tumors that oppress the main portal vein or main portal vein thrombus.
  • Patients that are accompanied with cavernous degeneration of portal vein.
  • Patients with hypersplenism caused by diseases of the blood system.
  • Patients suffer from serious acute and chronic diseases.
  • Patients with severe infectious diseases.
  • Patients with HIV-infectious or other AIDS-related disease.
  • Patients are drug abusers or have any psychological or mental conditions that potentially lead to poor study compliance.
  • Patients have any condition that in the judgement of the investigators would make the subject inappropriate for entry into this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

RECRUITING

Related Publications (1)

  • Liang BY, Zhang EL, Li J, Long X, Wang WQ, Zhang BX, Zhang ZW, Chen YF, Zhang WG, Mei B, Xiao ZY, Gu J, Zhang ZY, Xiang S, Dong HH, Zhang L, Zhu P, Cheng Q, Chen L, Zhang ZG, Zhang BH, Dong W, Liao XF, Yin T, Wu DD, Jiang B, Yuan YF, Zhang ZL, Chen YB, Li KY, Lau WY, Chen XP, Huang ZY. A combined pre- and intra-operative nomogram in evaluation of degrees of liver cirrhosis predicts post-hepatectomy liver failure: a multicenter prospective study. Hepatobiliary Surg Nutr. 2024 Apr 3;13(2):198-213. doi: 10.21037/hbsn-22-410. Epub 2023 Mar 15.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Surgically resected non-tumor liver tissues will be retained

MeSH Terms

Conditions

Carcinoma, HepatocellularLiver Cirrhosis

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Xiaoping Chen

    Tongji Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

August 13, 2019

First Posted

September 3, 2019

Study Start

August 1, 2019

Primary Completion

November 1, 2020

Study Completion

December 1, 2020

Last Updated

October 12, 2020

Record last verified: 2020-10

Locations